Attending #AANAM this week? Catch Dr. Sandra Smieszek from Vanda Pharmaceuticals presenting on VCA-894A, a custom therapeutic for a #CMT2S patient. @Hesperos's #HumanOnAChip model showed it improved neuromuscular function & supported its FDA Orphan Drug Designation.buff.ly/GroAbr2

Exciting news! U.S. FDA has announced a Roadmap to Reducing Animal Testing in Preclinical Safety Studies by leveraging more effective, human relevant methods - including #OrganOnAChip models like our #HumanOnAChip! buff.ly/BcxPIRQ #FDA #NAMs #AnimalTesting

Hesperos Co-founder and President Michael Shuler, PhD, is the keynote speaker at TECH NETWORK 's Innovations in Disease Modelling 2025! He'll discuss how #BodyOnAChip models like our #HumanOnAChip are advancing preclinical drug development. Register free buff.ly/v3EHyji

Congrats to our JHU CAAT colleagues on their latest article exploring the current landscape and future direction of #MPS! Timely insights, especially in light of the recent U.S. FDA roadmap to reduce reliance on animal models. Read more: buff.ly/ZrINaLk #NAMs #AltTox

Hesperos won the ACC.25 Pitch Challenge, hosted by American College of Cardiology! This shows the growing acceptance of our #HumanOnAChip especially with recent pronouncements from both the U.S. FDA and NIH supporting the adoption of #NAMs - including #OrganOnAChip models. buff.ly/QovBUbw

An insightful piece from C&EN (Chemical & Engineering News) on the recent FDA announcement, which includes a quote from Hesperos cofounder and Chief Scientist James Hickman, PhD. We’re glad to contribute to the broader conversation on this important topic!

Hesperos Chief Scientist is presenting today at Stanford Medicine’s Frontiers in Cardiovascular Science Symposium. He’ll share how our multi-organ #HumanOnAChip technology is accelerating therapeutic safety and efficacy evaluations. Watch free at: buff.ly/qtwtI2F

Join us for The 3Rs Collaborative (3RsC)'s Multi Organ MPS workshop today, May 27, 10am EST. Hesperos will be 1 of 11 companies presenting multi organ models. Learn about the incredible work companies are doing in this space! Register to watch free at buff.ly/4eVwZiB #3Rs #MPS #NAMs

We are looking forward to next week's MPS World Summit in Brussels! Members of our team will be presenting alongside other global leaders to discuss the latest advancements in organ-on-a-chip and other New Approach Methodologies (NAMs). Hope to see you there! #MPS2025 #NAMs

Planning to attend the MPS World Summit next week? Be sure to stop by Booth #301 to learn more about our Human-On-A-Chip technology. #MPS2025 #NAMs #Biotech #DrugDevelopment #OrganOnAChip

Today we announced our partnership with Hesperos, Inc. to advance preclinical development of our lead compound, PSIL-006, for the treatment of frontotemporal dementia (FTD). Read more: prnewswire.com/news-releases/… #FTD #Neuroplastogens #MindfulMedicine

We are pleased to announce an exciting project with Psilera, a biotech firm developing a novel psilocybin derivative for #FTD. We'll be supporting the preclinical development of PSIL-006, a promising new therapeutic candidate for this devastating disease. buff.ly/nYzJydp

The collaboration between Hesperos and Psilera reflects a shift toward technology like organ-on-a-chip being sought by U.S. FDA. hubs.li/Q03rl-Wm0

Hesperos will be at Biotechnology Innovation Organization's #BIO2025 next week! Connect with us at BioFlorida's Florida Pavilion, booth #778, to learn more about our Human-On-A Chip technology. Learn more about BIO at buff.ly/2ku2NlB #biotech #MPS #NAMs #OrganOnAChip

Chief Scientist James Hickman will be on the panel at tomorrow's virtual Animal-Free Workshop Series for Early Career Researchers, hosted by Physicians Committee and JHU CAAT, at 10 am EST. Register free at buff.ly/gTzodWV #NAMs #OrganOnAChip #HumanOnAChip #Biotech

The FDA is moving away from mandatory animal testing. This Genetic Engineering & Biotechnology News article highlights how the industry is responding with tools like Organ-on-Chip, organoids, and AI models. A great snapshot into what this means for the future of drug development. buff.ly/isMs7zx #FDA

New in Advanced Science: Our Human-on-a-Chip® platform was used to create what is believed to be the first digital twin from an organ-on-a-chip, predicting human efficacy and safety for antimalarial drugs. Read more: buff.ly/ZLqcigu #DigitalTwin #OrganOnAChip #NAMs

Join Chief Scientist J. Hickman next week for #ACSFall2025. His talk on Aug. 19 will cover how #HumanOnAChip systems are being used in pre-clinical drug discovery. Learn more at buff.ly/FXx1XUc #NAMs #OrganOnAChip #PreclinicalResearch #DrugDevelopment